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curable disability due to chromosome anomalies and other severe disorders detectable in early pregnancy. Such a service is most economically provided in conjunction with facilities-for genetic counselling and postnatal chromosome analysis. Dr The concept that many storage disorders result from deficiencies of specific lysosomal hydrolases has led to the recognition that the accumulation of the ganglioside Gm, in neurones of patients with Tay-Sachs disease is associated with a deficiency in the activity of the enzyme hexosaminidase component A. Laboratory diagnoses of this and of several other recessively inherited diseases can now be made on small specimens of leukocytes or cultured skin fibroblasts by assays of enzyme activities.
In the absence of feasible therapy for the management of inborn lysosomal disorders, attention has turned to control measures involving prenatal detection of the enzyme abnormality and selective abortion. At present, the most generally useful source of fetal material is derived from a culture of amniotic fluid cells obtained by transabdominal amniocentesis at about fourteen weeks gestation. Until several cases have been diagnosed in utero and confirmed by examination of fetal tissues, a laboratory which proposes to offer prenatal testing should not claim that such tests are reliable enough to be the basis of advice given to parents at risk who wish to have more children.
Although biochemical assays for the detection of carriers have been developed for several recessively-inherited disorders, the abnormal gene frequency is too low to make mass screening programmes practicable at present. Prenatal diagnosis is therefore restricted to pregnancies subsequent to the birth of an affected child in a family. However, among Ashkenazi Jews, one person in thirty is a heterozygote for Tay-Sachs disease and carrier detection programmes have already been started. Couples at risk can be identified before they start a family and thus control of this fatal disorder can be extended to every pregnancy. There are three main groups of conditions for which prenatal diagnosis, followed by selective termination, may be useful: chromosome anomalies, single gene determined conditions (especially inborn errors of metabolism) and the common congenital malformations. True prevention of chromosome anomalies is not in sight and for a reduction in their birth frequency we must rely on prenatal diagnosis and abortion. To some extent true prevention of single gene determined disorders, especially those which are autosomal recessive, is possible through carrier detection and genetic counselling; but prenatal diagnosis wilt be a valuable supplement. True prevention of the common congenital malformations such as those of the heart and the central nervous system, may be practicable in future by environmental protection of those genetically at risk; but this is not yet practicable and prenatal diagnosis and abortion offer the best prospects for an early reduction in their birth frequency. The two first and most immediate contributions of prenatal diagnosis and selective termination will be towards a reduction in the prevalence of severe mental retardation and of severe neurological handicap due to myelomeningocele.
Children with Down's syndrome, which has a birth frequency of about 1.5 per 1000 total births, now constitute between a quarter and a third of all severely retarded children of school age. Nearly half of them are born to the 10% of mothers who have children over the age of 35 years. There is still much to be learned about the safety of amniocentesis at 15 to 16 weeks of pregnancy, but it is perhaps not unreasonable to anticipate screening of all mothers over 35 years of age who wish for it within the next ten years, and thereafter a gradual extension to younger age groups. Ultimately this will lead to the prevention of the large majority of births of Down's syndrome.
The neural tube malformationsanencephaly and spina bifida cysticawith a birth frequency of about 2 and 2.5 per thousand total births respectively, account for about 1 in 5 of stillbirths and about 1 in 15 of infant deaths. It would be simple to add a-fetoprotein estimations to the studies made on amniotic fluid for chromosome anomalies. In the meantime, while the screening of all pregnancies for anencephaly by ultrasound is practicable, amniocentesis for all pregnancies is not practicable. Screening for myelomeningocele as a routine is, therefore, likely to depend on the reliability of maternal plasma a-fetoprotein levels as an indicator of a fetus with a neural tube malformation. Present indications are encouraging that maternal plasma levels determined by radioassay will detect a large majority of instances of anencephaly and fewer, but perhaps still a majority, of open cases of spina bifida cystica. They will therefore point to the cases where a test on amniotic fluid is desirable. It must be accepted that the minority of instances of spina bifida cystica with a good covering of skin will be missed on screening both by maternal plasma and amniotic fluid.
With inborn metabolic errors prenatal screening as a routine is, by and large, impracticable; there are so many of them and a specific test is required for each. One therefore needs to know in advance the pregnancies at risk of each specific type of inborn metabolic error. Since these are mostly recessive this implies carrier detection of both men and women at marriage or earlier or at least of women early in pregnancy and then their spouses if need be. At present this is worth while only for those recessive conditions which have a high frequency in a particular population and for which carrier tests are available. Tay-Sachs in Ashkenazi Jews provides a prototype. Sickle cell anaemia and thalassemia are common in men and women originating from West Africa and the Eastern Mediterranean respectively; prenatal diagnosis of these conditions is likely to become possible once a way is found of obtaining fetal blood prenatally, In the meantime carrier detection, which is already possible, for both of these conditions, combined with genetic counselling is practicable and desirable. The most useful tests in Europeans would be that for the carrier detection and prenatal diagnosis of cystic fibrosis, a condition which has a birth frequency of about 6 per 10 000 total births. This is likely to have to await the discovery of the specific enzyme defect in this condition and this may take perhaps another five years. It is difficult to predict the extent to which carriers of the same recessive gene will decide not to marry each other rather than to marry and make use of prenatal diagnosis; in either case the birth of affected children will largely be prevented.
Looking further ahead the most valuable development in prenatal diagnosis for child health would be the discovery of means of detecting the more serious congenital heart malformations. These have a combined birth frequency of about 5 per 1000 and, in spite of much expert surgery, account for about 1 in 10 of infant deaths. Perhaps improved fetal electrocardiography and access to fetal blood will make this possible in the not too distant future. Meeting 4 July 1974 at the Institute of Naval Medicine, Alverstoke, Hampshire
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